Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition

/in , , /by

SAN DIEGO —  Illumina, Inc. (NASDAQ: ILMN) announced today that it has filed an action in the General Court of the European Union asking for annulment of the European Commission’s decision asserting jurisdiction to review Illumina’s acquisition of GRAIL. The Commission asserted jurisdiction to review the acquisition under Article 22 of the EU Merger Regulation […]

Read more →

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

/in , /by

SAN DIEGO —  Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission (FTC)’s challenge to its previously announced acquisition of GRAIL, a pre-commercial company founded to accelerate early screening of cancer. Illumina will pursue its right to proceed with the transaction, the impact of which would […]

Read more →

In response to the rulings of the Patents Court within the High Court of Justice for England & Wales on 18th February 2021

/in , /by

MGI makes the following statement: We welcome the Court’s decision to give us the permission to appeal the judgment, and we intend to file its appeal with the Court of Appeal. As permitted by the Court, we will continue to supply sequencing reagents to our existing customers in the UK during the appeal period. Although MGI […]

Read more →

Maravai LifeSciences Expands Its Intellectual Property Portfolio

/in , , , /by

Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics SAN DIEGO — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s […]

Read more →

Agilent Wins Trade Secret and Patent Infringement Litigation

/in , /by

J&X Technologies to pay Agilent more than $1.25 million in damages for “willful and malicious” theft of Agilent trade secrets SANTA CLARA, Calif. — Agilent Technologies Inc. (NYSE: A) today announced it has won a judgement in federal court for patent infringement and trade secret misappropriation against Shanghai-based J&X Technologies. The court victory in the […]

Read more →

BioTek Receives Patent for Automated Media Exchange (AMX) Module for the MultiFlo FX Multi-Mode Dispenser

/in , /by

WINOOSKI VT, USA — BioTek Instruments, an Agilent Technologies, Inc., company, announces that it was granted a patent by the United States Patent and Trademark Office for the Automated Media Exchange (AMX) module for the MultiFlo FX Multi-Mode Dispenser. In cell biology workflows, the automated MultiFlo FX with AMX module enables hands-free, gentle, and highly consistent media exchanges […]

Read more →

In response to the ruling of the Patents Court within the High Court of Justice for England & Wales on 20 January 2021, MGI makes the following statement

/in , /by

We concur with the court’s ruling that Illumina’s European Patent (EP) 1 828 412 to methods of sequencing by synthesis using ascorbic acid is invalid for obviousness and that MGI’s CoolMPS sequencing method does NOT infringe this patent, and also the finding that MGI’s CoolMPS sequencing does NOT infringe the EP 2 021 415 to […]

Read more →

HTG Expands Patent Portfolio with New Canadian Patent for its Nuclease Protection Methods for Detection of Nucleotide Variants

/in , /by

TUCSON, Ariz. — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease Protection Methods for Detection of Nucleotide Variants.” The patented technology involves a nuclease protection method using wildtype […]

Read more →

SimplSeq Files Fourth Patent Application

/in , , , /by

Murrieta Genomics has announced that SimplSeq, Inc., a wholly owned subsidiary, has filed its fourth patent application to protect a new sample preparation technology that is designed to simplify the process for extracting, isolating, purifying and replicating DNA and RNA from biologic samples. “Our internal validation testing has delivered some very exciting data, and we […]

Read more →